Leukemia Research
Volume 28, Issue 3 , Pages 237-241 , March 2004

The soluble form of CD83 is present at elevated levels in a number of hematological malignancies

  • Barry D Hock

      Affiliations

    • Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    • Corresponding Author InformationCorresponding author. Tel.: +64-3-3640-579; fax: +64-3-3640-649.
    • ,
  • Lisa F Haring

      Affiliations

    • Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    • ,
  • Alexander Steinkasserer

      Affiliations

    • Department of Dermatology, University Erlangen-Nuremberg, Erlangen, Germany
    • ,
  • Karen G Taylor

      Affiliations

    • Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    • ,
  • William N Patton

      Affiliations

    • Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand
    • ,
  • Judith L McKenzie

      Affiliations

    • Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand

Received 5 March 2003 ,Accepted 7 July 2003.

References 

  1. Zhou L, Schwarting R, Smith HM, Tedder TF. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J. Immunol. 1992;149:735
  2. Zhou LJ, Tedder TF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 1995;154:3821
  3. Yamashiro S, Wang JM, Yang D, Gong WH, Kamohara H, Yoshimura T. Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood. 2000;96:3958
  4. Scholler N, Hayden-Ledbetter M, Hellstrom KE, Hellstrom I, Ledbetter JA. CD83 is a sialic acid-binding Ig-like lectin (Siglec) adhesion receptor that binds monocytes and a subset of activated CD8+ T cells. J. Immunol. 2001;166:3865
  5. Lechmann M, Krooshoop DJ, Dudziak D, Kremmer E, Kuhnt C, Figdor CG, et al.  The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J. Exp. Med. 2001;194:1813
  6. Sorg UR, Morse TM, Patton WN, Hock BD, Angus HB, Robinson BA, et al.  Hodgkin’s cells express CD83, a dendritic cell lineage associated antigen. Pathology. 1997;29:294
  7. Scholler N, Hayden-Ledbetter M, Dahlin A, Hellstrom I, Hellstrom KE, Ledbetter JA. Cutting edge: CD83 regulates the development of cellular immunity. J. Immunol. 2002;168:2599
  8. Hock BD, Kato M, McKenzie JL, Hart DN. A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. Int. Immunol. 2001;13:959
  9. Hock BD, Patton WN, Budhia S, Mannari D, Roberts P, McKenzie JL. Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients. Leukemia. 2002;16:865
  10. Patton WN, Hock BD, McKenzie JL, Haring LF, Estey E, Albitar M. Plasma levels of soluble CD86 are an independent prognostic marker in AML but not MDS. Blood 2002;100:2970.
  11. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, et al.  Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 1998;188:1359
  12. Jones SA, Horiuchi S, Novick D, Yamamoto N, Fuller GM. Shedding of the soluble IL-6 receptor is triggered by Ca2+ mobilization, while basal release is predominantly the product of differential mRNA splicing in THP-1 cells. Eur. J. Immunol. 1998;28:3514
  13. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 1994;300:281
  14. Heaney ML, Golde DW. Soluble cytokine receptors. Blood. 1996;87:847

PII: S0145-2126(03)00255-8

doi: 10.1016/S0145-2126(03)00255-8

Leukemia Research
Volume 28, Issue 3 , Pages 237-241 , March 2004

Article Tools

* Image Usage & Resolution